GSK’s otherwise decent Q1 performance was spoilt by currency – the CER revenue growth of 4% was offset by negative forex of 6%, culminating into a decline of 2% at reported level to £7.2bn. All revenue growth numbers at CER unless specified otherwise. Both pharma and consumer health grew by 2% to ~£4bn and ~£2bn, respectively, while vaccine shot up by 13% to £1.2bn. The main highlights of the quarter include a weak respiratory business, impressive uptake of
27 Apr 2018
Strong pound wipes out growth as pricing woes hit respiratory
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong pound wipes out growth as pricing woes hit respiratory
GSK plc (GSK:LON) | 1,638 -245.8 (-0.9%) | Mkt Cap: 67,914m
- Published:
27 Apr 2018 -
Author:
Kamla Singh -
Pages:
3
GSK’s otherwise decent Q1 performance was spoilt by currency – the CER revenue growth of 4% was offset by negative forex of 6%, culminating into a decline of 2% at reported level to £7.2bn. All revenue growth numbers at CER unless specified otherwise. Both pharma and consumer health grew by 2% to ~£4bn and ~£2bn, respectively, while vaccine shot up by 13% to £1.2bn. The main highlights of the quarter include a weak respiratory business, impressive uptake of